aTyr Pharma

company in San Diego, United States

ATYR Nasdaq ISIN US0021202025 SEC CIK 1339970 LEI 529900ENQUXMC5EBKO36
Follow aTyr Pharma Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0 −100% vs same quarter last year
Net income −$18.3M +29.1% vs same quarter last year
EPS, diluted −$7.43 +29.9% vs same quarter last year
Operating cash flow −$9.5M +53.6% vs same quarter last year
Revenue by quarter
$0
$0
$0
$190K
$0
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income14 fiscal years
  • Revenue
  • Net income
−$75M−$50M−$25M$0$25MFY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$190K−$74.1M
FY24$235K−$64M
FY23$353K−$50.4M
FY22$10.4M−$45.3M
FY21$0−$33.8M
FY20$10.5M−$16.2M
FY19$422K−$16.2M
FY18-−$34.5M
FY17-−$48.2M
FY16-−$57.9M
FY15-−$48M
FY14-−$24.4M
FY13-−$20M
FY12--
MarginsShare of revenue
  • Operating margin
  • Net margin
−60000%−40000%−20000%0%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−40856.3%−39009.5%
FY24−28899.6%−27243.8%
FY23−15557.8%−14274.5%
FY22−446.8%−436.5%
FY21--
FY20−152.2%−155.2%
FY19−5445%−3844.5%
FY18--
FY17--
FY16--
FY15--
FY14--
FY13--
FY12--
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$62.1M
FY24−$69.2M
FY23−$37.4M
FY22−$43.5M
FY21−$33.3M
FY20−$15.5M
FY19−$20.1M
FY18−$31.7M
FY17−$43.7M
FY16−$53.5M
FY15−$37.5M
FY14−$23.1M
FY13−$18M
FY12-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • aTyr Pharma
  • Healthcare median
−40000%−30000%−20000%−10000%0%FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearaTyr PharmaHealthcare median
FY25−39009.5%−30.6%
FY24−27243.8%−47%
FY23−14274.5%−58%
FY22−436.5%−80.4%
FY21-−71.8%
FY20−155.2%−62.2%
FY19−3844.5%−46.2%
FY18-−49.6%
FY17-−45.9%
FY16-−36%
FY15-−37.8%
FY14-−35.5%
FY13-−37.1%
FY12-−29.1%